« Return to News | Drug Sponsors

Valeant buys Johnson & Johnson skincare unit for $345 million

Tuesday, July 19, 2011 12:57 PM

Valeant Pharmaceuticals wants to become the world's biggest player in the skincare sector in about five years, its top executive told Reuters. The company has been signaling its intent with a string of recent mid-sized acquisitions in the highly fragmented but lucrative dermatology sector.

The specialty drug maker will pay $345 million to buy the skincare unit of Johnson & Johnson-owned Janssen Pharmaceuticals.

Valeant plans to continue making deals in dermatology as it looks to reach the top faster, chief executive Michael Pearson said. Once its recent deals close, the company will record about $1 billion in revenue from dermatology.

While there is significant competition in the dermatology arena, Valeant will be facing smaller rivals rather than the pharmaceutical giants, which have been beating a hasty retreat from the sector as they look to narrow their focus.

Pearson's philosophy has been to stay clear of the so-called Big Pharma companies but engage in partnerships with them instead. The company is still considering larger takeovers and can pull off a $6 billion deal, Pearson said.

"They're out there buying assets for cash flow and building a broad dermatology presence. It seems like a pretty sound strategy to me," Stifel Nicolaus analyst Annabel Samimy said. "The assets that they're buying are not necessarily the ones that require a significant amount of promotion or expense behind them."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.